Emerging treatments
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. Moreau P et al. N Engl J Med. 2016 Apr 28;374(17):1621-1634. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractorymultiple myeloma: dose selection for a phase 3 maintenance study. Gupta N et al. Invest New Drugs. 2016 Apr 2. [Epub ahead of print]. Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients…